Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsLAB -3.41%33 Earnings Yield (Joel Greenblatt) % is 57.14% as of Jun. 2026. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Standard BioTools ranks worse than 117785.51% on this metric.
Standard BioTools's Enterprise Value for the quarter that ended in Jun. 2026 was $-126.03 Mil.
Standard BioTools's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-72.16 Mil. Standard BioTools's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 57.14%.
The historical rank and industry rank for Standard BioTools's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LAB'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -30759.24 Med: -22.58 Max: 22214.84
Current: 37.17
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Standard BioTools was 22214.84%. The lowest was -30759.24%. And the median was -22.58%.
LAB's Earnings Yield (Joel Greenblatt) % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.86
vs LAB: 37.17
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Standard BioTools's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Standard BioTools (NAS:LAB) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Standard BioTools Earnings Yield (Joel Greenblatt) % Related Terms
Standard BioTools Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools Earnings Yield (Joel Greenblatt) % Chart
For the Medical Devices subindustry, Standard BioTools's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Earnings Yield (Joel Greenblatt) % falls into.
Standard BioTools Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Standard BioToolss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Standard BioTools's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.16 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 57.14% mean?
Standard BioTools (LAB) has a Earnings Yield (Joel Greenblatt) % of 57.14% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Standard BioTools and its competitors. According to the industry distribution chart, Standard BioTools ranks #999999 out of 849 companies in the Medical Devices & Instruments industry.
Is Standard BioTools' Earnings Yield (Joel Greenblatt) % too high?
Standard BioTools' current Earnings Yield (Joel Greenblatt) % is 57.14%. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.86. Standard BioTools' value of 57.14% is 6544.2% above this industry median. Based on the distribution chart, Standard BioTools ranks #999999 out of 849 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Earnings Yield (Joel Greenblatt) % compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #999999 out of 849 companies for Earnings Yield (Joel Greenblatt) %. This places Standard BioTools in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.86. Standard BioTools' value of 57.14% is 6544.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.86, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Earnings Yield (Joel Greenblatt) % of 57.14% is 6544.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Earnings Yield (Joel Greenblatt) % is 57.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 8.6% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 57.14% and 6544.2% above the Medical Devices & Instruments industry median of 0.86. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Standard BioTools (LAB), the current Earnings Yield (Joel Greenblatt) % is 57.14% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued.
The current stock price of $0.65 is trading 8.6% below its estimated GF Value™ of $0.71.
GuruFocus considers Standard BioTools to be Fairly Valued.
Key valuation signals for LAB:
Earnings Yield (Joel Greenblatt) %: 57.14%
GF Value™: $0.71 vs. price of $0.65 (8.6% below fair value)
Industry Position: 6544.2% above the Medical Devices & Instruments median (#999999 of 849)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score
Get the complete analysis for LAB
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
